Charles River Labs (CRL) Stock
Fundamentals
Recent news

Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan
Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan
CRL

Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
CRL

PGNY vs. CRL: Which Stock Is the Better Value Option?
PGNY vs. CRL: Which Stock Is the Better Value Option?
CRL

Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
CRL
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $2.76 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan
Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan
CRL

Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
CRL

PGNY vs. CRL: Which Stock Is the Better Value Option?
PGNY vs. CRL: Which Stock Is the Better Value Option?
CRL

Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
CRL

Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
CRL

Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
CRL

Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?
Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?
CRL

Is This the Right Time to Add CRL Stock to Your Portfolio?
Is This the Right Time to Add CRL Stock to Your Portfolio?
CRL

Wall Street Is Now Backing the Clarity Act. Here's the Most Likely Scenario for What Happens Next With Crypto.
Wall Street Is Now Backing the Clarity Act. Here's the Most Likely Scenario for What Happens Next With Crypto.
CRL

CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?
CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?
CRL
About Charles River Labs
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Birgit Girshick | CEO & Director | 1970 |
| Mr. Michael Gunnar Knell | Corporate Senior VP & Chief Accounting Officer | 1977 |
| Mr. Joseph W. LaPlume J.D. | Corporate Executive Vice President of Corporate Development & Strategy | 1974 |
| Ms. Victoria L. Creamer | Corporate Executive VP & Chief People Officer | 1970 |
| Mr. Glenn G. Coleman CPA | Corporate Executive VP & CFO | 1968 |
| Mr. Mark Mintz | Corporate EVP, Chief Information Officer & Global Shared Services | 1974 |
| Mr. Todd Spencer | Corporate Vice President of Investor Relations | — |
| Ms. Kerry Dailey | Corporate Senior VP & Chief Legal Officer | — |
| Ms. Amy E. Cianciaruso | Corporate Senior Vice President, Chief Communications Officer & Government Relations | — |
| Dr. Brian F. Bathgate Ph.D. | Corporate Senior Vice President of European Safety Assessment | 1960 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
10 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -2.5 | +7.7 | -16.9 | +4.3 | ||||||||
| 2022 | -8.9 | -13.2 | -0.2 | -16.3 | -4.8 | -6.8 | +14.5 | -17.8 | -3.2 | +4.2 | +10.3 | -3.7 |
| 2023 | +11.4 | -11.6 | -9.5 | -5.1 | +1.7 | +7.1 | +0.4 | -1.2 | -6.5 | -12.9 | +17.6 | +17.2 |
| 2024 | -7.7 | +15.8 | +2.5 | -14.8 | -10.4 | -0.6 | +20.1 | -18.6 | +2.6 | -8.0 | +10.0 | -8.3 |
| 2025 | -9.8 | +2.3 | -7.9 | -18.7 | +16.0 | +12.4 | +9.9 | -2.2 | -3.0 | +5.6 | -0.4 | +13.3 |
| 2026 | +4.0 | -16.3 | -3.4 | -4.5 | +9.0 | +24.6 | +1.5 | +24.8 | +3.7 |



